Fig. 5From: Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non–small cell lung cancer in ChinaICER scatterplot from probabilistic sensitivity analysisBack to article page
